Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05141240 · ClinicalTrials.gov registry record
A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 4,650
- Enrollment target
NCT05141240: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05141240 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4,650 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05141240 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 4,650 participants
- Enrollment target
Study Summary
This is a retrospective cohort study to assess the real-world analysis of concomitant medication use among metastatic breast cancer patients treated with CDK4/6 inhibitors utilizing the US Optum research administrative claims database.
Primary Outcome
Distribution of patients with a prescription fill of ribociclib, palbociclib, or abemaciclib at index treatment date will be present by frequency among all patients treated with CDK4/6
Interventions
- DRUG Palbociclib
- DRUG Abemaciclib
- DRUG Ribiciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,650 participants |
| Start Date | 2020-04-15 |
| Est. Completion | 2020-06-15 |
What the finished NCT05141240 record still lists
NCT05141240 is an observational study that tracks outcomes without assigning an intervention. Its 4,650 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Palbociclib is the first listed.
NCT05141240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05141240 about?
NCT05141240 is a clinical study titled "A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors". This is a retrospective cohort study to assess the real-world analysis of concomitant medication use among metastatic breast cancer patients treated with CDK4/6 inhibitors utilizing the US Optum research administrative claims database.
What is the current status of trial NCT05141240?
This trial is currently completed. The enrollment target is 4,650 participants. The study started on 2020-04-15. Estimated completion is 2020-06-15.
What interventions are being tested in trial NCT05141240?
The interventions under investigation include: Palbociclib (DRUG), Abemaciclib (DRUG), Ribiciclib (DRUG).
Who is sponsoring clinical trial NCT05141240?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06535139 · 4,630 participants · NA
ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention
- NCT04371900 · 4,700 participants · NA
Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1
- NCT05486572 · 4,700 participants · NA
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- NCT06888388 · 4,700 participants
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI